Esperion Therapeutics, Inc.
ESPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $1 | $0 | $0 |
| Enterprise Value | $1 | $1 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 6% | 26.8% | -6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 36.5% | 65.4% | 51.5% | 62.9% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -10.6% | 9.5% | -32.3% | -7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -35.9% | -15.4% | -62.2% | -30.8% |
| EPS Diluted | -0.2 | -0.024 | -0.21 | -0.11 |
| % Growth | -726.4% | 88.5% | -90.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |